Risk remains after first Pfizer Covid-19 shot, UK study finds
The immune response after just the first dose was weaker in people who had not previously been infected, leaving them at risk from new variants
30 April 2021 - 17:42
London — A single dose of Pfizer’s Covid-19 vaccine may not generate a sufficient immune response to protect against dominant new variants, except in people who have already been infected with Covid-19, according to a UK study published on Friday.
The Imperial College-led study, which looked at immune responses among healthcare workers in Britain after their first dose of the Pfizer shot, found that those who had previously had mild or asymptomatic infection had enhanced protection against more infectious mutated variants that emerged in Britain and SA...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.